



Published in final edited form as:

*Nat Neurosci.* 2008 November ; 11(11): 1283–1293. doi:10.1038/nn.2209.

## A central role for *Islet1* in sensory neuron development linking sensory and spinal gene regulatory programs

Yunfu Sun<sup>1,2</sup>, Iain M. Dykes<sup>3</sup>, Xingqun Liang<sup>1</sup>, S. Raisa Eng<sup>3</sup>, Sylvia M. Evans<sup>1,2,5</sup>, and Eric E. Turner<sup>3,4,5</sup>

<sup>1</sup>Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 93093.

<sup>2</sup>School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 93093.

<sup>3</sup>Department of Psychiatry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 93093.

<sup>4</sup>VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA 92161.

### Abstract

We have used conditional knockout strategies in mice to determine the developmental events and gene expression program regulated by the LIM-homeodomain factor *Islet1* in developing sensory neurons. Early development of the trigeminal and dorsal root ganglia are grossly normal in the absence of *Islet1*. However, from E12.5 onward, *Islet1* mutant embryos exhibit loss of the nociceptive markers *TrkA* and *Runx1* and a near absence of cutaneous innervation. Proprioceptive neurons characterized by the expression of *TrkC/Runx3/Etv1* are relatively spared. Microarray analysis of *Islet1* mutant ganglia reveals prolonged expression of developmental regulators normally restricted to early sensory neurogenesis, and ectopic expression of transcription factors normally found in the CNS but not in sensory ganglia. Later excision of *Islet1* does not reactivate early genes, but results in decreased expression of transcripts related to specific sensory functions. Together these results establish a central role for *Islet1* in the transition from sensory neurogenesis to subtype specification.

---

The peripheral sensory nervous system conveys information about the external world to the CNS, and is organized according to the location and modality of the sensory input. The general somatic senses include pain, touch, temperature and position, and are transduced by sensory neurons innervating the skin and musculoskeletal structures, termed nociceptors, mechanoreceptors, thermoreceptors and proprioceptors, respectively. At spinal levels, general somatic sensation is conveyed by the dorsal root ganglia (DRG), while in the anterior head and face, these sensory modalities are transmitted by the trigeminal ganglia (TG).

---

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

<sup>5</sup>To whom correspondence should be addressed at: [eturner@ucsd.edu](mailto:eturner@ucsd.edu), [syevans@ucsd.edu](mailto:syevans@ucsd.edu).

DRG neurons are derived from neural crest, while cranial sensory ganglia are derived from both neural crest and specialized placodes within the embryonic surface ectoderm. At all axial levels, the initial phase of sensory neurogenesis is dependent on the bHLH factors neurogenin1 (Neurog1) and neurogenin2 (Neurog2), with the expression and functional importance of Neurog1 predominating in the TG and DRG and Neurog2 playing a dominant role in sensory ganglia derived from the epibranchial placodes<sup>1, 2</sup>. In all sensory neurons, the expression of Neurog1 and/or Neurog2 is followed by the bHLH factors Neurod1 and Neurod4 (Math3), which are dependent on the neurogenins<sup>2</sup>.

The neurogenic phase of sensory development is followed by cell cycle exit, axon growth, and the expression of genes characteristic of neuronal function. Coincident with these events, beginning at E9.5–10.5 in mice, nearly all general sensory neurons co-express the pan-sensory homeodomain transcription factors Islet1 and Brn3a (product of the *pou4f1* gene)<sup>3</sup>. In mouse embryos lacking Brn3a, the DRG and TG exhibit defective axon growth, show abnormal persistence of early developmental transcription factors, and decreased expression of markers of multiple sensory subtypes<sup>4–6</sup>. Islet1 has been shown to be critical for early development of motor neurons<sup>7</sup>, but an essential role for this factor in cardiac development leads to embryonic death at approximately E10.8–10, and has prevented any significant examination of the role of Islet1 in sensory neurogenesis.

The terminal phase of sensory differentiation is characterized by the expression of developmental regulators that characterize distinct sensory modalities<sup>3, 11, 12</sup>. The neurotrophin receptors TrkA, TrkB and TrkC (products of the *Ntrk1*, *Ntrk2* and *Ntrk3* genes) are preferentially expressed in, and essential for the survival of, pain, touch and position-sensing neurons, respectively<sup>12</sup>. The runt family transcription factor Runx1 is expressed in nociceptors, and is required for the transition of TrkA<sup>+</sup> sensory precursors to Ret<sup>+</sup>/TrkA<sup>-</sup> non-peptidergic neurons<sup>14, 15</sup> and for the expression of sensory receptors of the TRP and Mrg families<sup>13</sup>. In contrast, the related factor Runx3 is required for the expression of proprioceptor markers in the DRG, and for the correct innervation of proprioceptor targets in the spinal cord and periphery<sup>16, 17</sup>. However, the relationship of the pan-sensory transcription factors to these subsequent events remains largely unknown.

To better understand the transition from sensory neurogenesis to subtype specification, we have used tissue-specific Cre-mediated recombination to excise *Islet1* in developing sensory precursors, and bypass the early embryonic lethality seen in constitutive *Islet1* knockouts. Initial neurogenesis appears normal in conditional *Islet1* knockout (CKO) sensory ganglia, but by embryonic day 12.5, excess apoptosis is observed, and at later stages ganglion size is markedly diminished. *Islet1* CKO embryos exhibit a profound loss of cutaneous innervation, and markers of neurons mediating pain and touch, including TrkA, TrkB, and Runx1, are markedly reduced, while mediators of proprioceptor development, such as TrkC and Runx3, are relatively preserved. Analysis of global gene expression in the DRG of *Islet1* CKO embryos reveals that Islet1 is required to terminate the expression of key regulators of the neurogenic phase of sensory development. Unexpectedly, Islet1 also acts as a repressor of transcription factors normally expressed in the spinal cord and hindbrain but not in sensory neurons. Delayed excision of *Islet1* using a tamoxifen-inducible system demonstrates that the early role of Islet1 in repression of neurogenic factors is separable from its later role as

an activator of functional sensory systems. Together these results define a gene expression program regulated by *Islet1* that occupies a pivotal position in the hierarchy of sensory development.

## RESULTS

### Generation of *Islet1* conditional knockout mice

To examine the initial formation of the sensory ganglia in mice lacking *Islet1*, we first interbred mice carrying a null allele of *Islet1* with mice carrying a *tauLacZ* reporter integrated into the *pou4f1* locus, *Brn3a<sup>tauLacZ</sup>*, in which  $\beta$ galactosidase ( $\beta$ gal) is expressed throughout the sensory nervous system<sup>18</sup>. We then interbred *Islet1<sup>+/-</sup>*, *Brn3a<sup>tauLacZ</sup>* mice with *Islet1* heterozygotes to yield *Islet1<sup>-/-</sup>*, *Brn3a<sup>tauLacZ</sup>* embryos. As expected, these embryos were growth arrested from approximately E9.57, and examination of *Islet1<sup>-/-</sup>* embryos at E10.5 revealed extensive necrosis (Fig. S1A). However,  $\beta$ gal staining showed that the DRG and TG had condensed and differentiated appropriately until this stage.

To overcome this early embryonic lethality, we adopted a conditional knockout strategy. A “floxed” *Islet1* allele (*Islet1<sup>F</sup>*) was generated in which *loxP* sites were inserted into the introns flanking exon 4 of the *Islet1* locus, which encodes the *Islet1* homeodomain (Figure S1B). The cre-deleter strain employed for these studies is a conventional transgenic *Wnt1-cre*, which has been shown to mediate *loxP* recombination in the dorsal neural tube and neural crest (Methods). Because *Wnt1-cre* activity is present in the neural tube by E8.5, prior to the onset of *Islet1* expression in the sensory ganglia, *Islet1<sup>F/F</sup>*, *Wnt1-cre* neurons should never express *Islet1*. Unless noted, comparisons were made between *Islet1<sup>F/F</sup>*, *Wnt1-cre* conditional knockout (CKO) embryos and *Islet1<sup>F/+</sup>*, *Wnt1-cre* controls. To identify cells in which cre-recombinase is active, and to trace the projections of neurons in which recombination has taken place, a *Rosa26-LacZ* allele was included in all experimental mice (Methods). In E12.5 DRG of *Islet1* CKO embryos expression of the targeted exon was less than 1% of that seen in control ganglia, indicating nearly complete excision, and effective loss of *Islet1* protein expression was also confirmed by immunofluorescence (Fig. S1C,D).

Newborn *Islet1* CKO mice appeared normal in gross morphology, but died within a few hours after birth. Body turning and limb movement of knockout mice were essentially indistinguishable from that of control littermates. However, *Islet1* CKO pups presented a reduced or minimal response to a mild noxious stimulus applied to the skin of the trunk or limbs, suggestive of deficits in cutaneous sensation.

Whole-mount  $\beta$ gal staining of *Islet1* CKO and control embryos showed that the DRG and TG condensed normally in mutant embryos, and at E11.5 the sensory ganglia were not obviously different from controls in whole-mount preparations (Fig. 1A). *Islet1* and *Brn3a* are expressed in terminally differentiating sensory neurons, whereas *Sox10* is expressed in sensory precursors, and is not normally co-expressed with *Islet1* in developing sensory ganglia (Fig. 1B). Thus failure to correctly initiate the terminal differentiation of sensory neurons might lead to persistent expression of *Sox10*, and/or a failure to initiate expression of *Brn3a*. However, DRG neurons of CKO embryos initiated expression of *Brn3a* normally, and did not co-express *Sox10* and *Brn3a* (Fig. 1C).

By E14.5 the DRG of *Islet1* CKO embryos were markedly smaller than those of controls (Fig. 1D,E). Because *Brn3a* expression is minimally affected in *Islet1* CKO ganglia, we used *Brn3a* as a marker for counting the differentiated sensory neurons in CKO and control ganglia. Although not significantly different at E11.5, the total neuron population was markedly lower in CKO ganglia by E14.5 (Fig. 1F). Because neurogenesis takes place in the DRG from E10 to E13.9, the reduced size of the sensory ganglia in *Islet1* CKO embryos at midgestation could be owing either to reduced generation of late-born sensory neurons or increased cell death. Increased apoptosis was confirmed by immunostaining with antibody to activated caspase-3 (Fig. 1G, Fig. S2), which showed that in the TG cell death is significantly increased at E11.5 and E12.5 in CKO embryos relative to control littermates, and in the DRG cell death is increased at E12.5. At E14.5 caspase3 labeling was comparable in *Islet1* CKO and control DRG, but in the context of diminished cell number in the mutant embryos. Thus it is likely that increased cell death between E12.5–E14.5 is the principal cause of the decreased size of the DRG in *Islet1* CKO embryos, although some contribution from reduced generation of late-born neurons cannot be excluded.

The sensory components of the peripheral nerves were specifically labeled by the expression of  $\beta$ galactosidase in *Islet1* CKO and control embryos. Overall, the peripheral nerves were diminished in CKO embryos, and the pattern of labeling indicated a modality-specific defect in sensory innervation. At thoracic levels in E14.5 embryos, the spinal nerves could be identified intercostally in CKO mice, but the cutaneous branch of the ventral ramus was absent, consistent with a complete loss of cutaneous sensory fibers subserving pain, touch and temperature (Fig. 1H), which is likely to be due at least in part to the neuronal death observed in the ganglion.

Detailed examination of the innervation of the distal limbs at E14.5 confirmed a nearly complete loss of fine cutaneous sensory fibers (Fig. 1I). Innervation of the central part of the forepaw and hindpaw, which contain intrinsic muscles that receive proprioceptive innervation, was preserved. Also preserved was a single sensory branch innervating one side of digits 1,2 and 5 in both the forelimb and hindlimb. To determine the nature of these spared sensory axons, we examined the expression of *TrkA* and *TrkC*, which mark nociceptive and proprioceptive sensory neurons, respectively, in digit 5 of control and CKO embryos (Fig. 1J). In controls, the sensory axon bundles in both the medial and lateral aspect of digit 5 were immunoreactive for *TrkA* and *TrkC*, indicating that they contain mixed sensory fibers. In CKO animals, the medial branch to digit 5 was absent, and the lateral branch was immunoreactive only for *TrkC*. These results indicate that the persisting sensory fibers in CKO embryos emanate from a subset of *TrkC*<sup>+</sup> proprioceptors.

### Selective loss of *TrkA* and *TrkB* neurons *Islet1* knockout DRG

To assess the role of *Islet1* in sensory subtype specification, we examined expression of *TrkA*, *TrkB* and *TrkC* in the DRG of *Islet1* CKO embryos and control littermates across development. In control embryos *TrkA* was detected from E11.5, and was extensively expressed at subsequent stages (Fig. 2A–D). *TrkC* was also widely expressed in the DRG at E11.5, and at this stage showed significant overlap with *TrkA*. However, consistent with

prior studies, from E12.5 onward TrkC was much more restricted in its expression, and the TrkA and TrkC expressing neurons were distinct populations<sup>20</sup>.

At E11.5, TrkA expression in the DRG of *Islet1* CKO embryos was comparable to controls, but by E12.5 it was significantly reduced (Fig. 2A,B,E). TrkC was not detected until E12.5, a delay of at least two developmental days relative to its normal onset of expression<sup>16</sup>. By E14.5, the number of TrkA<sup>+</sup> neurons in the *Islet1* CKO DRG was reduced to less than one-third of that observed in controls (Fig. 2C,E). TrkC<sup>+</sup> neurons were relatively spared, and appeared more dense relative to controls due to loss of ganglion volume (Fig. 2C,F). The few TrkA<sup>+</sup> neurons that survived to birth in mutant DRG expressed levels of TrkA similar to controls (Fig. 2D). Furthermore, no significant overlap in the expression of TrkA and TrkC was observed in mutant DRG neurons at later stages (Fig. 2C,D), suggesting that segregation of these two major neuronal subsets proceeds normally in the absence of *Islet1*.

Many TrkC<sup>+</sup> proprioceptors are born in an early wave of Ngn2-dependent neurogenesis, which is later compensated by Ngn1 if Ngn2 is absent<sup>1</sup>. The delayed expression of TrkC raised the possibility that the first wave of neurogenesis might be defective in *Islet1* CKO ganglia. To determine whether early TrkC neurogenesis takes place in *Islet1* CKO DRG, we injected pregnant mice with bromodeoxyuridine (BrdU) at E10.5, and examined the incorporation of the label in TrkC<sup>+</sup> neurons at E15.5. Total BrdU incorporation and specific labeling of TrkC neurons at E10.5 was not significantly different in *Islet1* CKO ganglia and controls (Fig. S3), indicating that lack of *Islet1* results in a delay in TrkC expression *per se*, rather than a delay in neurogenesis.

TrkB expression characterizes subsets of cutaneous mechanoreceptor neurons<sup>21</sup>. In *Islet1* CKO embryos, TrkB<sup>+</sup> neurons were detectable at E12.5, but reduced compared to controls (Fig. 2G). By E14.5, TrkB<sup>+</sup> neurons were markedly reduced (Fig. 2H), and similar results were obtained at P1 (data not shown).

TrkA and TrkC immunoreactivity were also used to examine the central projections of DRG neurons in the spinal cord. In control embryos at E14.5, TrkA<sup>+</sup> axons projected into the superficial layer (laminae I and II) whereas TrkC<sup>+</sup> afferents entered the spinal cord at a more medial position, and projected ventrally (Fig. 2I). In *Islet1* CKO embryos no TrkC expression in the dorsal root was detected at E11.5, consistent with the delay in TrkC expression observed in the ganglion, but TrkA<sup>+</sup> central projections were relatively normal (Fig. 2A). At E12.5 and E14.5, TrkA<sup>+</sup> central projections were greatly reduced (Fig. 2B,J). The majority of the remaining TrkA<sup>+</sup> fibers were appropriately confined to the superficial layers of the spinal cord, although aberrantly located fibers were also detected. In contrast, TrkC<sup>+</sup> central projections penetrated into the deep lamina in a manner similar to controls.

### ***Islet1* regulates subtype-specific transcription factors**

We next examined *Islet1* CKO embryos and controls for expression of key transcription factors known to regulate or interact with Trk receptors in sensory subtype specification. Prior work has shown that TrkA expression in the nociceptive population is intimately related to the transcription factor Runx1. In prenatal DRG development, most TrkA neurons express Runx1, and at P1 there is still a high degree of overlap. Postnatally, most Runx1<sup>+</sup>

sensory neurons downregulate TrkA and instead express Ret. In Runx1 knockouts, expression of TrkA and its co-localization with Ret are expanded 13, 15, 22.

Runx1 expression was detected beginning at E12.5 in control DRG, and was dramatically reduced in *Islet1* CKO mice at all developmental stages examined (Fig. 3A–C). As expected from prior studies, at P1 control ganglia had substantial populations of both Runx1<sup>+</sup>/Ret<sup>+</sup> and TrkA<sup>+</sup>/Ret<sup>+</sup> neurons. In the DRG of *Islet1* CKO embryos, both populations were markedly diminished, but the extent of co-expression of these markers was not affected (Fig. 3D).

We then examined the expression of Runx3 and the ets-domain transcription factor Etv1, both markers of proprioceptor populations (Fig. 3E–K). Runx3 and Etv1 were co-expressed with *Islet1* in a subset of DRG neurons at E11.5 (Fig. 3E,J). In contrast to the delayed expression of TrkC, Runx3 was expressed in *Islet1* CKO ganglia at E11.5 and Runx3 neurons were only slightly reduced compared to controls, indicating that the initiation of Runx3 expression is independent of both *Islet1* and TrkC (Fig. 3E–G). By E12.5 nearly all of the early Runx3 neurons co-expressed TrkC in control and CKO ganglia (Fig. 3H). Runx3/TrkC and Etv1/TrkC neurons were spared in CKO mice at E14.5 (Fig. 3I,K), and neurons expressing these markers comprised much of the vestigial ganglion remaining at P1 (Fig. S4).

We next considered possible mechanisms by which Runx3/Etv1/TrkC-expressing proprioceptors might escape *Islet1* dependence. These early-born neurons could represent a class of sensory neurons which do not express *Islet1*, and therefore do not require it, or they could be spared by a redundant function of the closely related factor *Islet2*, which is also expressed in the DRG. Although at E11.5 nearly all Etv1<sup>+</sup> DRG neurons co-expressed *Islet1*, by E14.5 there was almost no overlap between *Islet1* and Runx3 or Etv1 expression (Fig. 3L), indicating that these proprioceptors rapidly downregulate *Islet1* as they mature. *Islet2* expression follows *Islet1* by about one developmental day, and at E12.5, *Islet2* was expressed in a significant fraction of Etv1<sup>+</sup> neurons (Fig. S4B). However, Etv1 and *Islet2* were not co-expressed at E14.5 in control or CKO ganglia (Fig. S4C). Thus TrkC<sup>+</sup>/Runx3<sup>+</sup>/Etv1<sup>+</sup> proprioceptive neurons rapidly downregulate *Islet* factors as development progresses and subsequently develop by an *Islet*-independent pathway.

### Global gene regulation by *Islet1* in the sensory ganglia

To better understand the program of gene expression regulated by *Islet1*, we performed microarray analysis to examine changes in transcript levels in the DRG of CKO embryos compared to littermate controls. For these experiments, E12.5 embryos were chosen because it is the last stage at which the DRG do not exhibit a profound reduction in size resulting from apoptosis. Replicate assays of ganglia of the same genotype were highly reproducible, and comparison of *Islet1* control and CKO ganglia exhibited little variation for the large majority of transcripts, but a select number were markedly increased or decreased (Fig. S5).

Among the most-changed transcripts (Table 1 and Table 2), the majority of those with known expression patterns and functions were transcription factors or other kinds of developmental regulators. Other highly changed transcripts encode proteins which mediate



neural transmission, including channels, neuropeptides and receptors, participate in intracellular signal transduction, or play roles in axon, neurite or synapse formation. None of the highly changed transcripts represented “housekeeping” genes mediating general cellular processes, and the expression of most genes which are widely expressed in the nervous system, such as the neurofilaments, were also not significantly changed (Table 1).

The microarray results clearly demonstrate that the DRG of *Islet1* CKO mice fail to correctly execute a gene expression program characteristic of nociceptor differentiation. The nociceptive neuropeptides substance P (Tac1) and CGRP (Calra) were not yet expressed at E12.5. However, several pain-mediating channels and receptors expressed at this stage were among the most decreased transcripts (Table 2), including those encoding the sodium channel Nav1.8 (Scn10a), the neuropeptide galanin, the capsaicin receptor, Trpv111 and the Bv8 receptor/prokineticin receptor-1 (Prokr1), which partners with Trpv123. Microarray analysis also confirmed a marked decrease in TrkA and TrkB expression, while TrkC was not significantly changed (Fig. 4A). In addition, the nociceptive marker Runx1 was profoundly downregulated, while Runx3 was relatively spared. Multiple members of the Ets family, including Etv1, Etv4 (Pea3) and Etv5 (Erm) were also significantly decreased, but not absent, in CKO ganglia.

Microarray and RNA in situ analysis of *Islet1* CKO ganglia also revealed increased expression of transcription factors associated with early sensory neurogenesis (Fig. 4B,C, S6A). These included the neurogenic bHLH factor Neurog1 (Neurogenin1), known to be essential for early steps in sensory neurogenesis, the related bHLH factors Neurod1, Neurod4 and Neurod6, and the Zn-finger transcription factor insulinoma-associated 1 (Insm1, IA-1)<sup>24</sup>. Transcripts of multiple genes of the HoxA, B, and C clusters were increased, generally in the range of 1.5–2.5 fold (Fig. S6B). The increased expression of these genes, all of which normally exhibit strong expression in early sensory development and then decline with maturation, clearly results from a failure in their developmental repression. Changes in gene expression in the TG of *Islet1* CKO embryos closely paralleled the DRG for both the decreased and increased transcripts, despite the incomplete excision of the *Islet1* gene observed in the TG (Fig. 4C).

We also identified a second class of increased transcripts which are not normally expressed in the sensory ganglia at any phase of development (Fig. 5). These genes include the LIM-homeodomain factors Lhx1 (Lim1) and Lhx2 (LH2A), the transcriptional co-regulator Lbxcor1, and the bHLH factors Olig1 and Olig2. Although these factors are not expressed in the DRG, each has a known role in spinal cord development (Discussion). The transcription factor Tcfap2b (Ap2 $\beta$ , Fig. 5B) has characteristics of both classes of increased transcripts, in that it is normally expressed in early sensory development as are the bHLH genes, and is also expressed in postmitotic spinal neurons at E12.5. Lbxcor1 and Tcfap2b were strongly expressed only in a subset of DRG neurons in CKO embryos (Fig. 5B, enlarged views), perhaps owing to the activity of redundant repressive factors in the neurons which do not upregulate these genes.

Changes in gene expression in the TG closely followed those observed in the DRG for this class of increased genes. Lhx2 and Lbxcor1 were not expressed in the TG of E12.5 control

embryos (Fig. 5C), but were activated in the *Islet1* CKO TG, and were also expressed in the adjacent hindbrain. *Tcafp2b* also showed increased expression in *Islet1* CKO TG from low basal levels in control ganglia (Fig. 5C). Thus in the absence of *Islet1*, developing sensory neurons de-repress a gene expression program common to the spinal cord and hindbrain.

### Distinct early and late roles for *Islet1*

The changes in gene expression observed in sensory neurons lacking *Islet1* from the onset of development imply a role as a repressor of neurogenic genes, and also as an activator of sensory-specific phenotypes. However, the loss of sensory specific markers at later stages could be due in part to the death of subsets of neurons. In order to better distinguish early and late roles of *Islet1*, and to discriminate between specific gene regulation and the effects of cell loss, we adopted a delayed excision strategy using a tamoxifen-inducible MerCreMer recombinase targeted to the *Islet1* locus (*Islet1<sup>MCM</sup>*)<sup>25</sup>. *Islet1<sup>MCM/+</sup>* mice were interbred with *Islet1<sup>F/F</sup>* mice to produce *Islet1<sup>MCM/F</sup>* induced knockout (IKO) and *Islet1<sup>F/+</sup>* control ganglia. Cre-mediated excision was induced at E11.5, approximately two days after the onset of *Islet1* expression in the TG and cervical DRG. Like *Islet1* CKO mice, the IKO mice died in the perinatal period. The DRG and TG of the induced knockout embryos were analyzed at E14.5 and at E18.5, just prior to birth.

Immunofluorescence for *Islet1* protein (Fig. 6A–C) in the DRG and qPCR analysis of the targeted exon (Fig. 6F) in the TG indicated generally efficient excision of the *Islet1* homeodomain, with some residual *Islet1*<sup>+</sup> cells. In contrast, *Islet2* expression was preserved in the IKO DRG (Fig. 6D,E). Microarray analyses of the TG of E14.5 IKO and control embryos revealed that the early neurogenic genes (*Neurog1*, *Neurod1*, *Neurod4*) and mediators of spinal cord development (*Lhx1*, *Lhx2*, *Lbxcor1*, *Olig1*) which were markedly increased in the *Wnt1-Cre*-mediated CKO sensory ganglia were not increased in E14.5 IKO ganglia (Table S1), demonstrating that 2–3 days of *Islet1* expression at the onset of neurogenesis is sufficient to permanently repress these genes.

Transcripts which show decreased expression in *Islet1* CKO ganglia had a mixed expression pattern in the IKO TG at E14.5 (Table S2). Expression of *TrkA* and *TrkB* was maintained normally after delayed excision. Transcripts for several genes which define sensory phenotypes were significantly decreased, including, galanin, tyrosine hydroxylase, receptor channel *TrpV1* and serotonin receptor *5HTR3a* ( $p > 0.998$ , Fig. 6G, Table S2). Analysis of the full set of transcripts changed at E14.5 revealed *Islet1* dependence of several other neural genes which had not been detected at E12.5 (Fig. 6H), including serotonin receptor *5HTR3b* (*Htr3b*), synaptoporin (*Synpr*), sensory-specific sodium channel *NaV1.9* (*Scn11a*), metabotropic glutamate receptor *mGluR7* (*Grm7*), and the nociceptor-associated carboxypeptidase inhibitor latexin (*Lxn*).

In order to assess whether ongoing *Islet1* expression is necessary to maintain sensory survival, we also examined *Islet1* IKO DRG at E18.5 (Figure 7). Neuron number did not differ significantly between *Islet1* IKO ganglia and controls at this stage, *Runx1* and *TrkA* were expressed in a pattern similar to controls, and the expression of *Drg11* was maintained (Fig. 7E–J). However, the numbers of neurons expressing *TrpV1* and the menthol receptor *TrpM8* were markedly decreased (Fig. 7K–N). Taken together, the induced knockout results



show that a set of *Islet1* functions, including the repression of neurogenic and CNS-specific transcription factors, as well as maintenance of *TrkA*, *TrkB*, and cell survival in the nociceptor lineage, are unique to the early phase of *Islet1* expression. In contrast, continued expression of *Islet1* is required to maintain the expression of numerous genes that mediate specific sensory functions.

## DISCUSSION

### Pan-sensory homeodomain factors and the gene regulatory program of sensory development

*Islet1* is expressed at the transition from neurogenesis to terminal differentiation in sensory neurons at all levels of the neural axis, including the trigeminal ganglion, mesencephalic trigeminal, hindbrain sensory ganglia and DRG. In the present study we have used a conditional *Islet1* knockout model to bypass cardiac lethality and show that mice lacking *Islet1* have profound deficits in the sensory innervation of the CNS and periphery, extensive changes in sensory gene expression, and markedly increased sensory apoptosis, with relative sparing of proprioceptor neurons.

Throughout the sensory system, *Islet1* is co-expressed with another pan-sensory factor, the POU-homeodomain factor *Brn3a3*, 26. These factors share a common role in the repression of early sensory transcription factors, but their effects on the repression of CNS gene expression programs and on specific downstream sensory phenotypes are quite distinct. Furthermore, the common functions of *Brn3a* and *Islet1* do not result from cross-regulation of these genes. *Brn3a* expression is unaltered in the DRG of *Islet1* CKO mice, and *Islet1* expression does not significantly change in the *Brn3a* null DRG and TG5, 6. Thus *Brn3a* and *Islet1* have independent roles which intersect at the target gene level for a subset of their regulatory functions.

The principal common role of both factors is to terminate gene expression programs characteristic of early sensory precursors. At E12.5–E13.5, *Neurod1* and *NeuroD4* exhibit increased expression in both *Islet1* and *Brn3a* null mice, due to a failure in the normal developmental downregulation of these genes, which normally decline by midgestation5, 6, 27. In *Islet1* knockouts, expression of *Neurog1*, which precedes and is required for expression of the *NeuroD* class, also persists abnormally. Clearly related to this pathway is the increased expression of the Zn-finger factor *Insm1* in both knockouts, which is known to interact with *Neurod1*28. In the DRG, *Islet1* and *Brn3a* mutants also both fail to developmentally downregulate multiple members of the Hox A, B and C classes6.

### *Islet1* and the differentiation of sensory subtypes

Although *Islet1* and *Brn3a* have similar functions in the repression of early neurogenic factors, their roles in the development of sensory subtypes are distinct, with nociceptors and proprioceptors having greater dependence on *Islet1* and *Brn3a*, respectively. Because *Islet1* and *Brn3a* are initially expressed in all sensory precursors, they are unlikely to act as selective signals for subtype differentiation. Instead, it is likely that *Islet1* and *Brn3a* are permissive for the differentiation, or required for the survival, of specific subtypes.

In the nociceptive lineage of *Islet1* CKO mice, TrkA expression is initiated normally, but by E12.5 the number of TrkA<sup>+</sup> neurons and TrkA expression levels are markedly reduced, and few Runx1<sup>+</sup> neurons are detected at any stage. Because Runx1 is not dependent on TrkA for its initial expression<sup>15</sup>, the loss of Runx1 expression is probably not mediated solely by reduced levels of TrkA. Conversely, although misexpression of Runx1 can induce TrkA expression in sensory precursors<sup>29</sup>, TrkA is not dependent on Runx1<sup>13</sup>, suggesting that *Islet1* is upstream of both of these factors. TrkB expression levels are also markedly reduced in *Islet1* CKO ganglia, indicating a loss of cutaneous mechanoreceptors<sup>21</sup>.

In contrast to TrkA, *Islet1* CKO ganglia show selective sparing of TrkC<sup>+</sup> neurons, and most of the surviving TrkC<sup>+</sup> neurons also express Runx3 and Etv1, markers characteristic of early-born Ia proprioceptors<sup>1, 12</sup>. These neurons initially express *Islet1* and *Islet2*, but rapidly downregulate *Islet* expression, and appear to subsequently develop by an *Islet*-independent pathway. These subtype-specific deficits in *Islet1* knockout mice are clearly distinct from those seen in *Brn3a* null embryos, in which sensory ganglia exhibit early loss of TrkC<sup>30, 31</sup> and Runx3<sup>5, 6</sup> expression and loss of proprioceptive innervation of central and peripheral targets<sup>31, 32</sup>, and in which changes in the expression of TrkA, TrkB and Runx1 are relatively late and of smaller magnitude<sup>5, 30</sup>.

*Islet1* is also required for the normal expression of all members of the “Pea3 group” of Ets-family transcription factors in the DRG, which in addition to Etv1 includes Etv4 (Pea3) and Etv5 (ERM). Etv1 expression is maintained in TrkC<sup>+</sup>/Runx3<sup>+</sup> proprioceptors in the DRG of *Islet1* DKO mice, but overall Etv1 mRNA expression is reduced to ~40% of normal. In addition to the large Ia proprioceptors, Etv1 is expressed in small, later-developing neurons which co-express *Islet2*<sup>6</sup>, and the decrease in Etv1 expression probably represents the loss of this population. Expression of Etv4 and Etv5 has been described in the neural crest<sup>33</sup> and sensory ganglia<sup>34</sup>, and Etv4 has a known role in motor neuron development, but the specific functions of these factors in sensory development are not known. There is some evidence for redundancy of function in this gene class<sup>35</sup>, and understanding the specific roles of Etv4, Etv5, and the late expression of Etv1 may require analysis of compound loss-of-function embryos.

*Islet1* does not appear to affect TrkA expression via regulation of the Kruppel-like factor 7 (Klf7), which is expressed in the DRG and TG from the time of ganglion condensation and has been shown to have synergistic effects with *Brn3a* in the regulation of TrkA<sup>36</sup>. Klf7 expression is only modestly changed in the mid-gestation DRG of *Islet1* CKO and *Brn3a* KO mice (10–30% decrease, data not shown), and *Brn3a* expression also appears to be normal in *Klf7* knockout mice<sup>36</sup>. However, the expression of *Islet1* in *Klf7* knockout mice has not been reported, and given the profound effects of *Islet1* on TrkA expression, it may interact with or mediate the effects of Klf7.

*Islet1* is also required for the normal expression of Drg11 (*Prrxl1* gene product) a homeodomain protein expressed in peptidergic and nonpeptidergic nociceptors of the TG and DRG, and in their primary targets in the CNS, the trigeminal nucleus and spinal cord dorsal horn<sup>37, 38</sup>. Drg11 null mice exhibit delayed and defective nociceptive innervation of

the dorsal spinal cord<sup>37</sup>, and loss of *Drg11* expression may thus cause some of the defects in CNS innervation observed in *Islet1* null mice.

### **Islet1 function links sensory and spinal gene expression programs**

*Islet1* CKO mice exhibit derepression of multiple genes which have known roles in spinal cord development, but are not normally expressed in sensory ganglia, including *Lhx1*, *Lhx2*, *Lbxcor1*, *Olig1* and *Olig2*. The relationship between *Islet1* and *Lhx1* is especially instructive. In the spinal cord, *Islet1* has an essential role in the early survival of motor neurons<sup>7</sup>. *Islet1* is initially expressed in all neurons of the lateral motor column (LMC), which innervates the limb musculature. However, as motor differentiation progresses, motor neurons of the lateral subdivision of the LMC, which innervates dorsal muscle groups, activate the expression of *Lhx1*, and downregulate *Islet1*<sup>39</sup>. *Islet1* and *Lhx1* are not co-expressed, and misexpression studies of *Islet1* and *Lhx1* in this context have shown them to have a mutually repressive interaction<sup>40</sup>.

The corepressor *Lbxcor1* is expressed extensively in the dorsal cord, where it is co-expressed with *Lhx1/5* and *Brn3a*, and in scattered neurons in the ventral spinal cord. In both the dorsal and ventral spinal cord, *Lbxcor1*<sup>+</sup> neurons are interspersed with *Islet1*<sup>+</sup> cells, but their expression is mutually exclusive<sup>41</sup>. Furthermore, the transcriptional partner of *Lbxcor1*, *Lbx1*, represses *Islet1* in the dorsal spinal cord<sup>41–43</sup>. *Olig1* and *Olig2* are expressed in the spinal motor neuron progenitor (pMN) domain, and are necessary for the generation of motor neurons and oligodendrocytes from this region<sup>44</sup>. Although *Olig2* is required for motor neuron differentiation and the initiation of *Islet1* expression, it is rapidly downregulated as motor neurons differentiate<sup>45</sup>, and forced constitutive expression of *Olig2* inhibits *Islet1* expression<sup>46</sup>. It has not been determined whether *Islet1* plays an active role in terminating *Olig* expression in differentiating motor neurons, but the derepression of *Olig1/2* in sensory neurons in the absence of *Islet1* suggests that this is likely. Together these findings define a common set of targets for *Islet1* repression in spinal and sensory neurons.

### **Distinct early and late roles of Islet1**

Delayed induction of *Islet1* excision demonstrates that 2–3 days of early *Islet1* expression are sufficient to rescue many but not all aspects of the *Islet1* knockout phenotype. Specifically, transient expression is sufficient to permit cell survival, developmental repression of neurogenic genes, and normal levels of *TrkA*, *TrkB* and *DRG11*. Transient expression of *Islet1* also permanently represses the spinal cord/hindbrain gene expression program. However, several genes mediating specific sensory functions are *Islet1*-dependent in late gestation, including the neuropeptide galanin, receptors including *Htr3a*, *Htr3b*, *Grm7* and *Trpv1*, the sodium channel *Scn11a*, and tyrosine hydroxylase. Thus the neurogenic repressor functions of *Islet1* appear to be confined to the early stages of sensory differentiation, but a subset of its activator functions persist.

Multiple mechanisms may contribute to the persisting repression of *Islet1* targets in the delayed knockout ganglia. Partial compensation by *Islet2* may contribute, because in *Wnt1-cre* mediated *Islet1* knockout ganglia, *Islet2* is markedly decreased, but in the late *Islet1* knockout, *Islet2* is expressed at normal levels. However, the persistent repression of

neurogenic and CNS gene expression programs in the delayed knockout also suggests that transient expression of *Islet1* may induce lasting modifications of chromatin at these loci which maintain a repressed state<sup>47</sup>.

### Relationship of the role of *Islet1* in the nervous system to endocrine and cardiac development

In addition to its key roles in sensory and motor neuron development, *Islet1* is required for the development of pancreatic islet cells<sup>48</sup> and the cardiac progenitors which contribute a majority of cells to the developing heart<sup>8</sup>. One of the central questions regarding developmental transcription factors such as *Islet1*, which show cell-specific expression in diverse tissues, is whether they regulate similar or distinct programs of gene expression in different cell types. Two of the principal regulatory targets of *Islet1* in the sensory ganglia, *Neurod1* and *Insm1*, also play key roles in the pancreas, suggesting a conserved core gene regulatory network in sensory and islet cell development.

*Neurod1* null mice exhibit developmental apoptosis of  $\beta$ -islet cells, severe diabetes, and neonatal death<sup>49</sup>. In mice lacking *Insm1*, development of the pancreatic islet cells is arrested, and the principal products of the  $\alpha$ - and  $\beta$ -islet cells, glucagon and insulin, are markedly decreased<sup>24</sup>. *Islet1*, *Neurod1* and *Insm1* are all expressed in the pancreatic primordia from E9.5<sup>24, 48, 49</sup>, and in cell transfection studies, cross regulation of *Neurod1* and *Insm1* has been described<sup>28, 50</sup>, but the full regulatory relationship between these factors has not been determined. It will be interesting to see whether similar regulatory relationships pertain in neural and endocrine tissues, and also in cardiac progenitors, in which the downstream targets of *Islet1* are yet to be identified.

## METHODS

### Transgenic mice

Mice bearing a constitutive null allele of *Islet1* were a gift of Sam Pfaff<sup>7</sup>. The *Brn3a<sup>tau</sup>LacZ* mouse line has been previously described<sup>18</sup>. Generation of *Islet1<sup>MCM</sup>* (*MerCreMer*) mice has also been reported<sup>25</sup>. Details of the generation of *Islet1<sup>F</sup>* mice will be reported elsewhere. Briefly, a genomic fragment of encompassing exon 4 of mouse *Isl1* gene was cloned and a Neo-selectable targeting construct was generated in which this fragment is flanked by *loxP* sites (Fig. S1). Embryonic stem (ES) cells were electroporated with this construct and neomycin-resistant ES cell clones were screened for correct targeting of the *Isl1* locus by Southern analysis. Two recombinant clones were used for the blastocyst injection and chimeric mice were crossed to C57BL/6J females to generate heterozygous mice (*Islet<sup>F/+</sup>*). The Neomycin resistance gene was removed by crossing *Islet<sup>F/+</sup>* mice to a FLPeR deleter strain (Supplementary Methods online). *Islet1<sup>F/+</sup>* mice were intercrossed to generate homozygous floxed *Islet1* mice (*Islet1<sup>F/F</sup>*).

Methods for genetic crosses, tamoxifen-induced *Islet1* excision, tissue fixation, Xgal staining, immunostaining, in situ hybridization, microarray and Q-PCR analysis and in situ hybridization appear in the Supplementary Methods online. Primers for conventional and real-time genotyping of the floxed *Isl1* and *Wnt1-cre* alleles appear in Table S3.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

We would like to thank Drs. T. Jessell, S. Arber, L. Reichardt, M. Wegner, D. Lima and S. Pfaff for antibodies, and Drs. Qiufu Ma and Jane Johnson for in situ hybridization probes (Methods). We would also like to thank Dr. Nick Webster and Lutfunnessa Shireen of the UCSD/VA Microarray Core for assistance with microarray technology, and Gian Carlo Parico and Amanda Jackson for technical assistance. Mouse monoclonal antibodies were obtained from the Developmental Studies Hybridoma Bank, maintained under contract NO1-HD23144 from the NICHD. Supported in part by Department of Veterans Affairs MERIT funding, and NIH awards HD33442, MH065496 (E.E.T) and HL074066 (S.E.). E.E.T. is a NARSAD Investigator.


## REFERENCES

1. Ma Q, Fode C, Guillemot F, Anderson DJ. Neurogenin1 and neurogenin2 control two distinct waves of neurogenesis in developing dorsal root ganglia. *Genes Dev.* 1999; 13:1717–1728. [PubMed: 10398684]
2. Fode C, et al. The bHLH protein Neurogenin2 is a determination factor for epibranchial placode-derived sensory neurons. *Neuron.* 1998; 20:483–494. [PubMed: 9539123]
3. Anderson DJ. Lineages and transcription factors in the specification of vertebrate primary sensory neurons. *Current Opinion in Neurobiology.* 1999; 9:517–524. [PubMed: 10508743]
4. Eng S, et al. Defects in sensory axon growth precede neuronal death in Brn3a-deficient mice. *J. Neuroscience.* 2001; 21:541–549. [PubMed: 11160433]
5. Eng SR, Lanier J, Fedtsova N, Turner EE. Coordinated regulation of gene expression by Brn3a in developing sensory ganglia. *Development.* 2004; 131:3859–3870. [PubMed: 15253936]
6. Eng SR, Dykes IM, Lanier J, Fedtsova N, Turner EE. POU-domain factor Brn3a regulates both distinct and common programs of gene expression in the spinal and trigeminal sensory ganglia. *Neural Develop.* 2007; 2:3.
7. Pfaff SL, Mendelsohn M, Stewart CL, Edlund T, Jessell TM. Requirement for LIM homeobox gene *Isl1* in motor neuron generation reveals a motor neuron-dependent step in interneuron differentiation. *Cell.* 1996; 84:309–320. [PubMed: 8565076]
8. Cai CL, et al. *Isl1* identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. *Dev Cell.* 2003; 5:877–889. [PubMed: 14667410]
9. Moretti A, et al. Multipotent embryonic *isl1+* progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. *Cell.* 2006; 127:1151–1165. [PubMed: 17123592]
10. Sun Y, et al. *Islet 1* is expressed in distinct cardiovascular lineages, including pacemaker and coronary vascular cells. *Dev Biol.* 2007; 304:286–296. [PubMed: 17258700]
11. Woolf CJ, Ma Q. Nociceptors--noxious stimulus detectors. *Neuron.* 2007; 55:353–364. [PubMed: 17678850]
12. Marmigere F, Ernfors P. Specification and connectivity of neuronal subtypes in the sensory lineage. *Nat Rev Neurosci.* 2007; 8:114–127. [PubMed: 17237804]
13. Chen C-L, et al. *Runx1* Determines Nociceptive Sensory Neuron Phenotype and Is Required for Thermal and Neuropathic Pain. *Neuron.* 2006; 49:365–377. [PubMed: 16446141]
14. Yoshikawa M, et al. *Runx1* selectively regulates cell fate specification and axonal projections of dorsal root ganglion neurons. *Dev Biol.* 2007; 303:663–674. [PubMed: 17208218]
15. Kramer I, et al. A Role for *Runx* Transcription Factor Signaling in Dorsal Root Ganglion Sensory Neuron Diversification. *Neuron.* 2006; 49:379–393. [PubMed: 16446142]
16. Levanon D, et al. The *Runx3* transcription factor regulates development and survival of *TrkC* dorsal root ganglia neurons. *Embo J.* 2002; 21:3454–3463. [PubMed: 12093746]
17. Inoue K, et al. *Runx3* controls the axonal projection of proprioceptive dorsal root ganglion neurons. *Nat Neurosci.* 2002; 5:946–954. [PubMed: 12352981]

18. Quina LA, et al. Brn3a-expressing retinal ganglion cells project specifically to thalamocortical and collicular visual pathways. *J Neurosci.* 2005; 25:11595–11604. [PubMed: 16354917]
19. Lawson SN, Biscoe TJ. Development of mouse dorsal root ganglia: an autoradiographic and quantitative study. *J Neurocytol.* 1979; 8:265–274. [PubMed: 490183]
20. Farinas I, Wilkinson GA, Backus C, Reichardt LF, Patapoutian A. Characterization of neurotrophin and Trk receptor functions in developing sensory ganglia: direct NT-3 activation of TrkB neurons in vivo. *Neuron.* 1998; 21:325–334. [PubMed: 9728914]
21. Fundin BT, et al. Differential dependency of cutaneous mechanoreceptors on neurotrophins, trk receptors, and P75 LNGFR. *Dev Biol.* 1997; 190:94–116. [PubMed: 9331334]
22. Luo W, et al. A hierarchical NGF signaling cascade controls Ret-dependent and Ret-independent events during development of nonpeptidergic DRG neurons. *Neuron.* 2007; 54:739–754. [PubMed: 17553423]
23. Vellani V, et al. Sensitization of transient receptor potential vanilloid 1 by the prokineticin receptor agonist Bv8. *J Neurosci.* 2006; 26:5109–5116. [PubMed: 16687502]
24. Gierl MS, Karoulias N, Wende H, Strehle M, Birchmeier C. The zinc-finger factor Insm1 (IA-1) is essential for the development of pancreatic beta cells and intestinal endocrine cells. *Genes Dev.* 2006; 20:2465–2478. [PubMed: 16951258]
25. Laugwitz KL, et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. *Nature.* 2005; 433:647–653. [PubMed: 15703750]
26. Fedtsova N, Turner E. Brn-3.0 Expression identifies early post-mitotic CNS neurons and sensory neural precursors. *Mechanisms of Development.* 1995; 53:291–304. [PubMed: 8645597]
27. Lanier J, Quina LA, Eng SR, Cox E, Turner EE. Brn3a target gene recognition in embryonic sensory neurons. *Dev Biol.* 2007; 302:703–716. [PubMed: 17196582]
28. Breslin MB, Zhu M, Lan MS. NeuroD1/E47 regulates the E-box element of a novel zinc finger transcription factor, IA-1, in developing nervous system. *J Biol Chem.* 2003; 278:38991–38997. [PubMed: 12890672]
29. Marmigere F, et al. The Runx1/AML1 transcription factor selectively regulates development and survival of TrkA nociceptive sensory neurons. *Nat Neurosci.* 2006; 9:180–187. [PubMed: 16429136]
30. Huang E, et al. POU domain factor Brn-3a controls the differentiation and survival of trigeminal neurons by regulating Trk receptor expression. *Development.* 1999; 126:2869–2882. [PubMed: 10357931]
31. McEvelly RJ, et al. Requirement for Brn-3.0 in differentiation and survival of sensory and motor neurons. *Nature.* 1996; 384:574–577. [PubMed: 8955272]
32. Ichikawa H, Mo Z, Xiang M, Sugimoto T. Effect of Brn-3a deficiency on parvalbumin-immunoreactive primary sensory neurons in the dorsal root ganglion. *Brain Res Dev Brain Res.* 2004; 150:41–45. [PubMed: 15126036]
33. Paratore C, Brugnoli G, Lee HY, Suter U, Sommer L. The role of the Ets domain transcription factor Erm in modulating differentiation of neural crest stem cells. *Dev Biol.* 2002; 250:168–180. [PubMed: 12297104]
34. Chotteau-Lelievre A, Desbiens X, Pelczar H, Defossez PA, de Launoit Y. Differential expression patterns of the PEA3 group transcription factors through murine embryonic development. *Oncogene.* 1997; 15:937–952. [PubMed: 9285689]
35. Hippenmeyer S, et al. A developmental switch in the response of DRG neurons to ETS transcription factor signaling. *PLoS Biol.* 2005; 3:e159. [PubMed: 15836427]
36. Lei L, Zhou J, Lin L, Parada LF. Brn3a and Klf7 cooperate to control TrkA expression in sensory neurons. *Dev Biol.* 2006; 300:758–769. [PubMed: 17011544]
37. Chen ZF, et al. The paired homeodomain protein DRG11 is required for the projection of cutaneous sensory afferent fibers to the dorsal spinal cord. *Neuron.* 2001; 31:59–73. [PubMed: 11498051]
38. Rebelo S, Chen ZF, Anderson DJ, Lima D. Involvement of DRG11 in the development of the primary afferent nociceptive system. *Mol Cell Neurosci.* 2006; 33:236–246. [PubMed: 16978876]




39. Kania A, Johnson RL, Jessell TM. Coordinate roles for LIM homeobox genes in directing the dorsoventral trajectory of motor axons in the vertebrate limb. *Cell*. 2000; 102:161–173. [PubMed: 10943837]
40. Kania A, Jessell TM. Topographic motor projections in the limb imposed by LIM homeodomain protein regulation of ephrin-A:EphA interactions. *Neuron*. 2003; 38:581–596. [PubMed: 12765610]
41. Mizuhara E, Nakatani T, Minaki Y, Sakamoto Y, Ono Y. Corl1, a novel neuronal lineage-specific transcriptional corepressor for the homeodomain transcription factor Lbx1. *J Biol Chem*. 2005; 280:3645–3655. [PubMed: 15528197]
42. Gross MK, Dottori M, Goulding M. Lbx1 specifies somatosensory association interneurons in the dorsal spinal cord. *Neuron*. 2002; 34:535–549. [PubMed: 12062038]
43. Muller T, et al. The homeodomain factor lbx1 distinguishes two major programs of neuronal differentiation in the dorsal spinal cord. *Neuron*. 2002; 34:551–562. [PubMed: 12062039]
44. Zhou Q, Anderson DJ. The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification. *Cell*. 2002; 109:61–73. [PubMed: 11955447]
45. Novitsch BG, Chen AI, Jessell TM. Coordinate regulation of motor neuron subtype identity and pan-neuronal properties by the bHLH repressor Olig2. *Neuron*. 2001; 31:773–789. [PubMed: 11567616]
46. Lee SK, Lee B, Ruiz EC, Pfaff SL. Olig2 and Ngn2 function in opposition to modulate gene expression in motor neuron progenitor cells. *Genes Dev*. 2005; 19:282–294. [PubMed: 15655114]
47. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. *Nature*. 2007; 447:425–432. [PubMed: 17522676]
48. Ahlgren U, Pfaff SL, Jessell TM, Edlund T, Edlund H. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. *Nature*. 1997; 385:257–260. [PubMed: 9000074]
49. Naya FJ, et al. Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/neuroD-deficient mice. *Genes Dev*. 1997; 11:2323–2334. [PubMed: 9308961]
50. Liu WD, Wang HW, Muguira M, Breslin MB, Lan MS. INSM1 functions as a transcriptional repressor of the neuroD/beta2 gene through the recruitment of cyclin D1 and histone deacetylases. *Biochem J*. 2006; 397:169–177. [PubMed: 16569215]



**Figure 1. Defective development of the DRG and spinal nerves in *Islet1* conditional knockout mice**

The sensory ganglia in control and CKO embryos were compared at E11.5 (A–C) and E14.5 (D,E, H–J). Presence of a conditional *Rosa26-LacZ* allele, activated by *Wnt1-cre*, allowed staining of sensory and autonomic ganglia and their axons in whole embryo preparations. In cranial regions, extensive staining was also seen in other neural crest-derived tissues. (A) *LacZ* staining of E11.5 embryos showing grossly normal morphology and normal-sized DRG in *Islet1* CKO embryos at this stage. (B) *Islet1* expression in differentiating neurons of E11.5 control ganglia. *Islet1*<sup>+</sup> neurons no longer express *Sox10*, a marker of multipotent precursors and glia. (C) Normal initiation of *Brn3a* expression in E11.5 CKO embryos. *Sox10* is characteristic of DRG precursors and is not co-expressed with *Brn3a* in either genotype. Occasional appearance of co-labeling is due to nuclear overlap. (D,E) Thoracic region of whole-mount Xgal stained, hemisected E14.5 embryos, showing marked reduction of the DRG in the CKO specimen. There is also profound reduction of the sympathetic chain

ganglia (arrowheads). **(F)** Brn3a immunoreactivity as a measure of neuronal number in E11.5 and E14.5 DRG. Asterisks indicate statistical significance (t-test) for a given comparison. E11.5,  $p=0.38$ ; E14.5,  $p < 0.001$ . **(G)** Increased cell death in the TG and DRG of CKO embryos. Caspase-3 immunoreactive cells were counted in 6–10 slides for each sample. E11.5 TG,  $p < 0.001$ ; E12.5 TG,  $p < 0.001$ ; E12.5 DRG  $p=0.02$ . **(H)** The mid-thoracic body wall of a hemisected E14.5 embryo, showing  $\beta$ galactosidase expression activated by *Wnt1-cre* in the sensory but not the motor component of the intercostal nerves. In CKO embryos, labeling of the intercostal nerves is diminished but detectable, however the cutaneous branches (arrows in top panel) are absent. The esophagus is prominent in the lower panel but is out of the plane of focus in the top panel. **(I)** Innervation of the distal forelimb and hindlimb at E14.5. In CKO embryos fine cutaneous sensory branches are lost throughout the limb (inset views). In the digits, labeled sensory axons persist only in a single fiber bundle in a corresponding position in digits 1, 2, and 5 of both the forelimb and hindlimb (arrowheads). **(J)** Immunofluorescence for TrkA and TrkC in sensory fiber bundles innervating digit 5. In control embryos, sensory fibers are immunoreactive for both TrkA and TrkC. In CKO embryos, the medial axon bundle adjacent to digit 4 is not labeled, and the persisting fiber bundle is immunoreactive for TrkC only (arrows). Legend: 1–5, digits 1–5; SC, spinal cord; T1, T6, thoracic dorsal root ganglion 1, 6. Error bars in all figures indicate mean  $\pm$  S.D.



**Figure 2. Neurotrophin receptor expression in sensory ganglia lacking Islet1**

(A–D) Expression of TrkA and TrkC in the brachial level DRG of control and CKO embryos of the specified developmental stages. TrkC expression is delayed until E12.5 in *Islet1* CKO ganglia. However, there is a subsequent loss of TrkA<sup>+</sup> neurons and relative sparing of TrkC<sup>+</sup> cells at later stages. TrkA immunoreactivity is also diminished in sensory fibers in the dorsal root (arrows, B). (E–F) Cell counts for TrkA and TrkC immunoreactive neurons. For control versus CKO: TrkA E11.5  $p=0.39$ ; E14.5  $p=0.0002$ ; TrkC E12.5  $p=0.24$ ; E14.5  $p=0.0002$  (increase). (G–H) TrkB expression is markedly diminished from

E12.5 onward in the DRG of *Islet1* CKO embryos. (**I–J**) TrkA and TrkC expression in the spinal projections of sensory neurons at E14.5. Innervation of the superficial layers of the spinal cord by TrkA fibers is markedly reduced, and ectopic fibers are observed (arrows, J). TrkC immunoreactive fibers appear undiminished, and project ventrally in both control and mutant specimens (arrowheads, I, J). SC, spinal cord.


Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





**Figure 3. Expression of transcription factors regulating sensory subtype specification is altered in the DRG of *Islet1* CKO embryos**

(A,B) Runx1 expression in the brachial level DRG at E12.5 and E14.5, showing markedly diminished expression in CKO ganglia. (C,D). Runx1, Ret and TrkA expression in P1 DRG. Subsets of neurons expressing all combinations of these markers appear markedly diminished in CKO DRG. (E–G) Runx3 and Islet1 expression in the DRG of control and CKO embryos at E11.5. In control embryos, Runx3 immunoreactive neurons are a subset of Islet1<sup>+</sup> cells. However, in the absence of Islet1, Runx3 expression is largely preserved. In G the number of Runx3 cells shows a modest decrease in CKO ganglia which did not reach




statistical significance. **(H,I)** Runx3 and TrkC expression at E12.5 and E14.5. Neurons expressing these proprioceptive markers are relatively spared in *Islet1* CKO ganglia, and account for an increasing fraction of the remaining DRG neurons as development progresses. **(J,K)** At E11.5, *Islet1* is co-expressed with *Etv1* in a subset of DRG neurons. At E14.5, *Etv1*<sup>+</sup> neurons are relatively spared, and nearly all co-express TrkC, indicating that they are highly overlapping with the Runx3/TrkC population. **(L)** At 14.5, *Islet1* is extensively co-expressed with Runx1 but is no longer co-expressed with Runx3 or *Etv1*. Mot, motor neurons; SC, spinal cord.

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript



#### Figure 4. *Islet1* regulates early and late programs of sensory gene expression

Microarray analysis of E12.5 DRG reveals coordinated changes in expression of gene families regulating specific phases of sensory development. (A) Factors associated with sensory subtype specification, including members of the Trk, Runx and Ets families, show profound decreases for genes associated with nociceptive neurons and little or no change for markers of proprioceptive neurons. (B) Neurogenic genes of the bHLH family, associated with early steps in sensory differentiation, are increased in *Islet1* CKO DRG. (C) Gene expression changes for NeuroD4 and Insm1 are concordant in the DRG and TG. Asterisks indicate significant increase or decrease (change  $p < 0.002$  or  $> 0.998$ ) in two independent comparisons. Scale: 200 $\mu$ m.



**Figure 5. Ectopic activation of spinal/hindbrain gene expression in *Islet1* CKO sensory ganglia**  
**(A)** Microarray analysis of E12.5 DRG reveals abnormal expression of transcription factors usually associated with spinal neuron development (Lhx1, Lhx2, Olig1, Olig2, Lbxcor1), and decreased expression of *Isl2*. LIM-interacting proteins of the Ldb and LMO families, which are normally expressed in both sensory ganglia and spinal cord, show relatively modest changes. Asterisks indicate significant increase or decrease (change  $p < 0.002$  or  $> 0.998$ ) in two concordant comparisons. **(B)** In situ hybridization shows expression of increased transcription factors increased in *Islet1* CKO embryos in the spinal cord and DRG.


*Islet1* CKO views are shown at higher magnification to reveal detail. (C) Concordant abnormal expression of CNS transcription factors in the E12.5 trigeminal ganglia. DRG, dorsal root ganglion; HB, hindbrain; SC, spinal cord; TG, trigeminal ganglion. Scale: B, 100 $\mu$ m; C, 200 $\mu$ m.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




**Figure 6. Late excision of *Islet1* supports nociceptor survival but alters downstream gene expression**

*Islet1*<sup>F/F</sup> and *Islet1*<sup>CreER/+</sup> mice were interbred to produce *Islet1*<sup>F/+</sup> control and *Islet1*<sup>F/CreER</sup> IKO embryos. Tamoxifen was administered to pregnant animals at E11.5 and embryos were examined at E14.5 or E18.5. Because of the need to assess the extent of *Islet1* knockdown in each experiment, in E14.5 IKO embryos the DRG were analyzed by immunofluorescence for *Islet1* expression, and the TG of the same embryos were used for microarray analysis. (A–C) Knock-down of *Islet1* protein in cervical-level DRG at E14.5. Note that *Islet1*

expression is also missing from the motor area of the spinal cord (mot). Arrows in (B) show examples of a small number of neurons in which recombination has not occurred. (A) and (B) were processed on the same slide and photographed at the same exposure. In (C) LacZ expression is activated from a Rosa26-LacZ reporter allele by the induced Cre. (D,E) Islet2 expression in control and IKO E14.5 DRG. (F) Exon-specific *Islet1* mRNA levels determined by qPCR in DRG of IKO embryo relative to control (1.0). Exon 4 is flanked by *loxP* sites. (G) Effect of late *Islet1* excision on gene expression in the E14.5 TG. Genes are displayed in the order of fold decrease in E12.5 DRG (Table 2). Asterisks indicate significant increase or decrease (change  $p < 0.002$  or  $> 0.998$ ) in two independent comparisons. (H) Additional late *Islet1* targets identified in E14.5 IKO TG.





#### Figure 7. Analysis of *Islet1* induced knockout DRG at E18.5

Excision of the *Islet1* homeodomain was induced by tamoxifen injection at E11.5 (Figure 6, Methods), and embryos were analyzed at E18.5. (A–C) Knockdown of *Islet1* expression assessed by immunofluorescence. *Islet1* expression is absent in the dorsal interneuron (dl) and motor neuron (mot) pools, and markedly diminished in the DRG. In (C), co-immunofluorescence for βgal expressed from the *Rosa26-LacZ* allele reveals a small population of *Islet1*<sup>+</sup> neurons in which recombination has not taken place (red). In the spinal cord, βgal immunoreactivity identifies some surviving motor neurons. However, the dl interneurons are represented only by small, dense particles of βgal immunoreactivity, consistent with cellular debris (dashed line), suggesting that the dl population is dependent on *Islet1* for survival. Matched sections were processed on the same slide and photographs were taken with the same exposure parameters. (D) *Brn3a* immunoreactivity was used to count neurons in lumbar DRG of Control and IKO embryos. Ten matched sections from control and IKO ganglia were counted, revealing no significant difference in neuronal number, and demonstrating that late expression of *Islet1* is not required for DRG viability. Two-tailed T-test for difference between control and IKO,  $p = 0.93$ . (E–F) *Runx1* immunoreactivity was near normal in IKO ganglia, in contrast to the marked decrease observed in CKO mice. (G–J) *TrkA* and *Drg11* expression did not appear different in Control and IKO ganglia. (I–L) Expression of the nociceptive markers *TrpV1* and *TrpM8*, evaluated by in situ hybridization, was diminished in IKO ganglia. *TrpV1* cells/section: Control  $N=10$ , mean  $5.9 \pm 3.1$ , range 2–12; IKO  $N=10$ , mean  $1.2 \pm 1.2$ , range 0–3. T-test for difference between control and IKO,  $p = 0.0003$ . *TrpM8* cells/section: Control  $N=10$ , mean

16.8  $\pm$ 5.3, range 11–23; IKO N=10, mean 5.3  $\pm$ 2.5, range 2–10. T-test for difference between control and IKO  $p = 3 \times 10^{-7}$ .

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

Transcripts showing increased expression in E12.5 DRG of *Islet1* CKO embryos.

Gene Title	Symbol	Class	WT	KO	Fold†
LIM homeobox 1	Lhx1	TX	11	362	32.3
Sal-like 3	Sall3	TX	9	269	30.4
Ladybird homeobox 1 corepressor 1	Lbxcor1	TX	39	1169	30.2
LIM homeobox 2	Lhx2	TX	78	1522	19.5
Oligodendrocyte transcription factor 2	Olig2	TX	18	136	7.6
Syntaxin binding protein 6	Stxbp6	Syn	146	853	5.8
Transcription factor AP-2 beta	Tcfap2b	TX	368	1986	5.4
Dishevelled associated activator of morphogenesis 1	Daam1	ST	51	262	5.1
Neuro-oncological ventral antigen 1	Novo1	Other	342	1624	4.8
FAT tumor suppressor 4	Fat4	ST	537	2450	4.6
Cellular retinoic acid binding 1	Crabp1	ST	1199	5449	4.5
Macrophage expressed gene 1	Mpeg1	Unk	127	529	4.2
Glycoprotein m6a	Gpm6a	AX	508	2026	4.0
Glycine receptor, alpha 2	Glr2	NT	51	205	4.0
Protocadherin 20	Pcdh20	AX	439	1572	3.6
ELMO domain containing 1	Elmod1	ST	174	609	3.5
Oligodendrocyte transcription factor 1	Olig1	TX	50	173	3.5
Cathepsin S	Ctss	Other	283	985	3.5
Protocadherin 9	Pcdh9	AX	373	1252	3.4
Paired-Ig-like receptor A2	Pir2	Unk	202	676	3.4
Disabled homolog 1	Dab1	ST	102	341	3.3
Dachshund 2	Dach2	TX	246	812	3.3
Eyes absent 1 homolog	Eya1	TX	196	629	3.2
Neurogenic differentiation 4	Neurod4	TX	1062	3140	3.0
<b>Selected:</b>					
K <sup>+</sup> channel, Shal-related 2	Kcnd2	NT	129	378	2.9
Short stature homeobox 2	Shox2	TX	403	1179	2.9

Gene Title	Symbol	Class	WT	KO	Fold†
Receptor tyrosine kinase-like orphan receptor 1	Ror1	ST	424	1207	2.8
Homeo box C6	HoxC6	TX	218	620	2.8
Insulinoma-associated 1	Insm1	TX	1684	4579	2.7
Neurogenin 1	Neurog1	TX	1749	4688	2.7
<b>Unchanged transcripts:</b>					
Microtubule-associated protein tau	Mapt	AX	4321	3615	n.s.
Neurofilament, light	Nefl	AX	22510	21551	n.s.
Neurofilament, medium	Nef3	AX	20951	18597	n.s.
Peptidylprolyl isomerase A (cyclophilin A)	Ppia	Other	25173	25452	n.s.

AX, axonogenesis; Dev, development; NT, neurotransmission; ST, signal transduction; Syn, synaptogenesis; TX, transcription; Unk, unknown.

Table 2

Transcripts showing decreased expression in E12.5 DRG of *Isl1/1* CKO embryos.

Gene Title	Symbol	Class	WT	KO	Fold↓
Na <sub>v</sub> 1.8	Scn10a	NT	148	6	24.7
Galanin	Gal	NT	3155	172	18.4
Runt related txn factor 1	Runx1	TX	684	51	13.4
Cholecystokinin A receptor	Cckar	NT	139	11	12.6
Musculin	Msc	TX	500	46	10.8
Homeo box D1	Hoxd1	TX	847	79	10.7
Basonuclin 1	Bnc1	TX	1125	108	10.5
Follistatin	Fst	Dev	606	92	6.6
Neurotrophic tyrosine kinase, receptor, type 1; TrkA	Ntrk1	Dev	2211	462	4.8
Phospholipase A2, group VII	Pla2g7	Unk	776	182	4.3
Protein tyrosine phosphatase, receptor type, J	Ptpnj	ST	2108	505	4.2
Advillin	Avil	NT	2257	557	4.1
Ig superfamily containing leucine-rich repeat 2	Islr2	Unk	1294	333	3.9
Tyrosine hydroxylase	Th	NT	1369	352	3.9
BMP-binding endothelial regulator	Bmper	Dev	602	155	3.9
Protein phosphatase 1, regulatory subunit 2	Ppp1r2	Unk	1902	509	3.7
Limb expression 1 homolog	Lix1	Unk	717	193	3.7
Ets variant gene 5	Etv5	TX	1847	496	3.7
Formin 1	Fmn1	Unk	813	218	3.7
Prokineticin receptor 1	Prokr1	NT	538	146	3.7
Dedicator of cytokinesis 10	Dock10	Unk	821	224	3.7
Contactin 4	Cntn4	AX	477	133	3.6
Protein kinase, cGMP-dep, type II	Ptkg2	ST	395	111	3.6
Ser/arg-rich protein specific kinase 3	Srpk3	Unk	356	103	3.5
Cerebellin 2 precursor protein	Cbln2	Unk	1260	368	3.4
Prostaglandin I receptor	Ptgir	St	485	144	3.4
Neurotrophic tyrosine kinase, receptor, type 2; TrkB	Ntrk2	Dev	1437	440	3.3
Doublecortin and CaM kinase-like 3	Deamk3	Unk	885	286	3.1

Gene Title	Symbol	Class	WT	KO	Fold↓
BTB domain containing 11	Btbd11	Unk	870	283	3.1
Insulin related protein 2	Isl2	TX	1408	465	3.0
Transient receptor potential cation channel, V 1	Trpv1	NT	140	47	3.0
<b>Selected:</b>					
5-HT receptor 3A	Htr3a	NT	312	107	2.9
Regulator of G-protein signalling 10	Rgs10	ST	2299	817	2.8
H6 homeo box 1	Hmx1	TX	2373	852	2.8
Ets variant gene 1	Etv1	TX	2604	986	2.6
Drg11	Prrxl1	TX	3208	1620	2.0